The Evaluation of Effects, Mechanisms, and Clinical Data of Avelumab

Abstract

Immune checkpoint inhibitors (ICI), the new frontier in the fight against cancer, have attracted much attention in the past few years. Among all types of ICIs, Avelumab is one of the most experimented upon because it is advantageous compared to other more traditional types of treatments like radiotherapy and surgery. Avelumab is capable of eliminating cancer from some patients who do not respond to the traditional treatments, or when their cancers reappear after being treated. Avelumab can target cancer more specifically, with minimal damage to other body cells like the death of hair follicles that result from chemotherapy. Though it is an effective treatment, there are a few areas in which it can improve, including lowering its costs, decreasing the risk of irAE, and making it effective to more patients. This paper will mainly discuss the history, mechanism, limitations, and treatment of different cancers using Avelumab, and focus on analyzing data on the effectiveness and performance of Avelumab in clinical trials when it is used to treat different cancers.